Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts
Published: April 03, 2026 by: 24/7 Wall Street
Sentiment: Neutral
One of the world's leading healthcare names, Novo Nordisk (NYSE:NVO) cut prices on Wegovy and Ozempic by up to 48% in India at the start of April 2026, a direct response to low-cost generic semaglutide flooding the market.
Read More
Pricing and availability of Novo, Lilly's weight-loss drugs
Published: April 01, 2026 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has approved Eli Lilly's oral weight-loss drug, orforglipron, branded as Foundayo, making it the second pill to enter the fast-growing obesity treatment market.
Read More
The FDA approved Eli Lilly's new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market
Published: April 01, 2026 by: WSJ
Sentiment: Positive
The FDA go-ahead tees up a battle with rival Novo Nordisk over the next front in the booming weight-loss drug market.
Read More
NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
Published: April 01, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk stock jumps after launching a Wegovy subscription plan to cut costs, expand telehealth access and improve treatment adherence for sustained obesity care.
Read More
Lilly and Novo Show How AI Is Rewiring Big Pharma
Published: March 31, 2026 by: PYMNTS
Sentiment: Positive
Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug development in ways that are beginning to reshape how fast new medicines reach patients. Eli Lilly signed a $2.
Read More
Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes
Published: March 27, 2026 by: Zacks Investment Research
Sentiment: Positive
NVO secures FDA nod for Awiqli, a once-weekly basal insulin for type II diabetes, strengthening its portfolio and showing strong efficacy in studies.
Read More
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Published: March 25, 2026 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
Read More
Jefferies trims Novo Nordisk target as GLP-1 pricing erosion and oral Wegovy launch uncertainty cloud first quarter
Published: March 24, 2026 by: Proactive Investors
Sentiment: Negative
The broker retains its hold rating, warning that overall portfolio growth may stall even as the oral weight-loss pill gains traction Jefferies has trimmed its price target on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant, to DKK270 from DKK275, maintaining a 'hold' rating ahead of first-quarter results. The change came as the broker flagged mounting uncertainty around GLP-1 pricing, oral Wegovy's launch trajectory and the risk that the new pill cannibalises rather than grows the overall franchise.
Read More
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
Published: March 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk's FDA nod for higher-dose Wegovy could boost healthcare ETFs' appeal, offering diversified exposure to the obesity drug market.
Read More
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
Published: March 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk faces slowing growth and rising competition, while Structure Therapeutics shows strong obesity study results, highlighting a clash of stability vs. upside.
Read More
Novo Nordisk: Priced For Disaster
Published: March 23, 2026 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk shares have slumped despite a promising partnership with Hims & Hers Health to distribute semaglutide drugs via telehealth platform. The agreement grants HIMS access to FDA-approved Ozempic and Wegovy in multiple dosages, expanding patient reach and options. The Wegovy pill continues to enjoy strong prescription growth via first-mover advantage.
Read More
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
Published: March 20, 2026 by: Zacks Investment Research
Sentiment: Positive
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April 2026.
Read More
China expresses hopes over Novo Nordisk's presence in market
Published: March 20, 2026 by: Reuters
Sentiment: Positive
China hopes Novo Nordisk will "continue to cultivate the Chinese market and contribute to building a healthy China," said Ling Ji, China's vice commerce minister, during a meeting with an executive VP from the Danish drugmaker on Friday, the ministry said.
Read More
A high dose of Wegovy helped people lose 21% of their weight. It was just approved.
Published: March 19, 2026 by: Market Watch
Sentiment: Positive
Novo Nordisk's 7.2 mg dose of Wegovy will compete against Lilly's GLP-1 injection.
Read More
Novo Nordisk's Higher Dose Wegovy Weight-Loss Drug Gains U.S. Approval
Published: March 19, 2026 by: WSJ
Sentiment: Positive
The Danish drugmaker said the accelerated approval was based on results from its Step Up trial, which showed 20.7% mean weight loss for participants with obesity.
Read More
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
Published: March 19, 2026 by: CNBC
Sentiment: Positive
The Food and Drug Administration approved a higher dose version of Novo Nordisk's blockbuster weight loss injection Wegovy, as the company pushes to win back market share from Eli Lilly. The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
Read More
FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
Published: March 19, 2026 by: PRNewsWire
Sentiment: Neutral
Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment* with Wegovy ® HD (~19% regardless of whether patients stayed on treatment**) in the STEP UP trial1 In the STEP UP trial, about one in three trial participants taking Wegovy® HD achieved 25% weight loss or higher1 This approval for Wegovy® further expands its already robust label inclusive of multiple formulations, including Wegovy® pill, and indications not available with other GLP-1 weight loss medicines PLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval …
Read More
TrumpRx lists many medicines at prices higher than paid in UK
Published: March 18, 2026 by: Reuters
Sentiment: Negative
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, according to a Reuters comparison of publicly available prices.
Read More
Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
Published: March 18, 2026 by: CNBC
Sentiment: Negative
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
Read More
Novo's Quiet Comeback Begins
Published: March 09, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk ended its dispute with Hims & Hers Health, enabling Wegovy distribution across a digital platform serving roughly 2.5 million subscribers. Novo Nordisk maintains exceptional profitability with an 82.41% gross margin and 45.50% EBIT margin, significantly exceeding sector medians. FY25 net profit reached DKK 100 billion while operating cash flow approached DKK 120 billion, supporting major CapEx, acquisitions, and shareholder returns.
Read More
Novo's Quiet Comeback Begins
Published: March 09, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk ended its dispute with Hims & Hers Health, enabling Wegovy distribution across a digital platform serving roughly 2.5 million subscribers. Novo Nordisk maintains exceptional profitability with an 82.41% gross margin and 45.50% EBIT margin, significantly exceeding sector medians. FY25 net profit reached DKK 100 billion while operating cash flow approached DKK 120 billion, supporting major CapEx, acquisitions, and shareholder returns.
Read More
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
4 Factor Dividend Growth Strategy Remains Ahead Of Its Benchmark
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Positive
The 4-Factor Dividend Growth Portfolio, a rules-based alternative to SCHD, targets high-quality, growth-oriented dividend stocks using four equally weighted metrics. Since inception, the strategy has delivered a 14.17% annualized return, maintaining a 2.12% annualized outperformance over SCHD despite recent SCHD momentum. The portfolio emphasizes strong free cash flow, robust dividend growth, high return on invested capital, and above-average yields, with low monthly turnover.
Read More
Why Novo Nordisk's Ireland expansion is key to fighting off Eli Lilly
Published: March 02, 2026 by: CNBC
Sentiment: Positive
Novo Nordisk is investing $506 million to expand manufacturing capabilities in Ireland. The move will strengthen its ability to meet both current and future demand for its oral medicines, said Novo executive Kasper Bødker Mejlvang.
Read More
Election of employee representatives to the Board of Directors of Novo Nordisk A/S
Published: March 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 2 March 2026 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S.
Read More
Monday's Market Movers: CRWD Rallies, NVO Downgrade, BRK/B Earnings
Published: March 02, 2026 by: Schwab Network
Sentiment: Positive
As markets grapple with the U.S. and Israel joint attack on Iran, Diane King Hall turns to stock movers kicking off the new trading week. CrowdStrike's (CWRD) upgrade from Piper Sandler signals what the firm calls a "best in class" cybersecurity platform that didn't deserve a part in the software sell-off.
Read More
Is Novo Nordisk's GLP-1 Dominance Fading After Lilly's Clinical Wins?
Published: March 02, 2026 by: Zacks Investment Research
Sentiment: Negative
NVO shares plunge 21% after Lilly's Zepbound and oral orforglipron beat its key GLP-1 drugs in head-to-head obesity and diabetes studies, respectively.
Read More
Why I'm Still Bullish On Novo Nordisk Despite Recent Setbacks
Published: February 27, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk is repriced as if its fundamentals have sharply deteriorated, despite strong underlying demand and market expansion drivers. NVO projects a 5-13% decline in 2026 sales and profits, mainly due to U.S. price compression, yet international growth and robust cash flow persist. Oral Wegovy's rapid adoption and Medicare coverage expansion present significant tailwinds, offsetting recent clinical and pricing setbacks.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
Published: February 26, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406